The monovalent XBB.1.5 COVID-19 vaccine is effective against XBB and JN lineage hospitalization; however, protection against the latter may be attenuated.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

With the U.S. Food and Drug Administration and Centers for Disease Control and Prevention approval of new mRNA COVID-19 ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Respiratory illnesses like influenza, COVID-19 and Respiratory Syncytial Virus (RSV) are known to spread more rapidly during ...

The Florida Department of Health, run by Surgeon General Dr. Joseph Ladapo, just released guidance on COVID-19 vaccines based ...